세계의 ANCA 관련 혈관염 시장 보고서(2025년)

Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Global Market Report 2025

US $ 4,490 ￦ 6,156,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 8,898,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 11,640,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

ANCA 관련 혈관염 시장 규모는 향후 수년간 강력한 성장이 전망될 예정입니다. 자가 면역 질환의 이환율의 상승, 면역계 기능 부전의 사례 증가, 다양한 관련 리스크 인자의 유병률의 상승 등에 기인한다고 생각됩니다. 이 기간에 예상되는 주요 동향에는 맞춤형 의료의 대두, 전략적 제휴, 진단 검사의 진보, 원격 의료의 채용 확대, 병용 요법의 개발 등이 있습니다.

자가면역질환의 유병률 증가는 향후 몇 년간의 ANCA 관련 혈관염 시장의 성장을 가속할 것으로 예측됩니다. 감염과 오염물질에 노출되는 기회가 늘어나는 것은 면역관용을 방해하고 비정상적인 면역반응을 유발함으로써 크게 기여하고 있습니다. 2023년 9월, 크론병과 궤양성 대장염 환자의 생활개선을 목적으로 하는 캐나다를 거점으로 하는 조직, 염증성 장질환(IBD) 임상연구센터가 발표한 IBD의 영향 보고서 2023에 따르면 10만명당 825명, 합계 32만명 이상에 영향을 미칠 것으로 알려져 있습니다. 유병률은 연간 2.44% 증가할 것으로 예상되며, 2035년에는 캐나다 인구의 1.1%에 상당하는 약 47만명이 앓고 있을 것으로 추정됩니다.

ANCA 관련 혈관염 시장의 주요 기업은 이 희귀하고 심각한 질병을 가진 환자에게 새로운 치료 옵션을 제공하기 위해 표적 치료제와 같은 혁신적인 솔루션의 개발을 선호합니다. ANCA 관련 혈관염에 대한 표적 치료법은 염증과 혈관 손상을 일으키는 면역성분을 특이적으로 저해하는 특수한 생물학적 제제를 이용하는 것으로, 이로써 질병의 진행을 억제하고, 종래의 치료와 관련된 부작용을 경감합니다. Vifor Fresenius Medical Care Renal Pharma(VFMCRP)는 리툭시맙 또는 시클로포스파미드 기반 요법과 함께 ANCA 관련 혈관염(AAV)을 치료하는 Tavneos(avacopan)에 대한 호주 정부의 규제 기관인 Therapeutic Goods 관리(TGA)로부터 승인을 받았으며, Tavneos는 ANCA 관련 혈관염의 두 가지 주요 병형인 다발혈관염성 육아종증(GPA) 및 현미경적 다발혈관염(MPA)에 특화되어 개발된 최초의 표적 치료제이기 때문에 이번 승인은 중요한 이정표가 됩니다. 이 치료제는 보체 C5a 수용체(C5aR1)를 선택적으로 저해함으로써 작용하며, 장기간에 걸쳐 심각한 부작용으로 알려진 고용량의 글루코코르티코이드(스테로이드)에 대한 의존성을 감소시키면서 염증과 질병의 진행을 관리하는 데 도움이 됩니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 금리, 인플레이션, 지정학, 무역전쟁과 관세, 코로나 태와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

• 세계의 ANCA 관련 혈관염 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
• 최종 이용 산업의 분석
• 세계의 ANCA 관련 혈관염 시장 : 성장률 분석
• 세계의 ANCA 관련 혈관염 시장 실적 : 규모와 성장, 2019-2024
• 세계의 ANCA 관련 혈관염 시장 예측 : 규모와 성장, 2024-2029, 2034F
• 세계의 ANCA 관련 혈관염 전체 시장 규모(TAM)

제6장 시장 세분화

• 세계의 ANCA 관련 혈관염 시장 : 유형별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 다발혈관염성 육아종증(GPA 또는 웨게너 육아종증)
• 현미경적 다발혈관염(MPA)
• 호산구성 다발혈관염성 육아종증(EGPA 또는 처그·스트라우스병)
• 기타 유형
• 세계의 ANCA 관련 혈관염 시장 : 치료별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 면역억제제
• 코르티코스테로이드
• 생물학적 제형
• 기타 치료법
• 세계의 ANCA 관련 혈관염 시장 : 진단별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 혈액검사
• 생검
• 화상 진단
• 기타 진단
• 세계의 ANCA 관련 혈관염 시장 : 다발혈관염성 육아종증(GPA 또는 웨게너 육아종증), 유형별 서브세그먼테이션: 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 한국성 다발혈관염성 육아종증
• 중증 다발혈관염성 육아종증
• 난치성 다발혈관염성 육아종증
• 세계의 ANCA 관련 혈관염 시장 : 현미경적 다발혈관염(MPA), 유형별 서브세그먼테이션: 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 신장 현미경적 다발혈관염
• 폐현미경적 다발혈관염
• 신경학적 현미경적 다발혈관염
• 세계의 ANCA 관련 혈관염 시장 : 호산구성 다발혈관염성 육아종증(EGPA 또는 처그·스트라우스병), 유형별 서브세그먼테이션: 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 심장 호산구성 육아종증 다발혈관염
• 폐호산구성 육아종증 다발혈관염
• 신경학적 호산구성 다발혈관염성 육아종증
• 세계의 ANCA 관련 혈관염 시장 : 기타 유형, 유형별 세분화: 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 약제 유발성 ANCA 관련 혈관염
• 감염 관련 ANCA 관련 혈관염
• 중첩 증후군 ANCA 관련 혈관염

제7장 지역별/국가별 분석

• 세계의 ANCA 관련 혈관염 시장 : 지역별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 세계의 ANCA 관련 혈관염 시장 : 국가별, 분석과 예측, 2019-2024, 2024-2029F, 2034F

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

• ANCA 관련 혈관염 시장 : 경쟁 구도
• ANCA 관련 혈관염 시장 : 기업 프로파일
  • F. Hoffmann-La Roche AG : 개요, 제품 및 서비스, 전략 및 재무 분석
  • Thermo Fisher Scientific Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
  • AstraZeneca Plc : 개요, 제품 및 서비스, 전략 및 재무 분석
  • Novartis AG : 개요, 제품 및 서비스, 전략 및 재무 분석
  • GlaxoSmithKline plc : 개요, 제품 및 서비스, 전략 및 재무 분석

제31장 기타 주요 기업 및 혁신 기업

• Amgen Inc.
• Fresenius Medical Care(FMS)
• Boehringer Ingelheim International GmbH
• Otsuka Holdings Co. Ltd.
• Biogen Inc.
• Quest Diagnostics Inc
• Csl Behring AG
• ARUP Laboratories
• Sebia Inc.
• Exagen Inc.
• Argenx SE
• Arkana Laboratories
• Alentis Therapeutics AG
• Hansa Biopharma AB
• InflaRx NV

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

• ANCA 관련 혈관염 시장 2029: 새로운 기회를 제공하는 국가
• ANCA 관련 혈관염 시장 2029: 새로운 기회를 제공하는 부문
• ANCA 관련 혈관염 시장 2029: 성장 전략
  • 시장 동향에 기초한 전략
  • 경쟁 전략

제36장 부록

SHW

영문 목차

영문목차

Antineutrophil cytoplasmic antibody (ANCA) associated vasculitis is a rare autoimmune disorder marked by inflammation and damage to small and medium-sized blood vessels, primarily affecting organs such as the kidneys, lungs, and respiratory tract. If left untreated, it can lead to serious complications. This condition intersects with nephrology, pulmonology, and rheumatology, and requires a multidisciplinary approach involving immunosuppressive therapies, corticosteroids, and advanced treatment strategies to prevent organ failure and enhance long-term outcomes.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary types of ANCA-associated vasculitis include granulomatosis with polyangiitis (GPA or Wegener's), microscopic polyangiitis (MPA), eosinophilic granulomatosis with polyangiitis (EGPA or Churg-Strauss), and other variants. Granulomatosis with polyangiitis (GPA), previously known as Wegener's granulomatosis, is a systemic form of AAV characterized by granuloma formation and inflammation in small to medium-sized vessels, often impacting the respiratory system, kidneys, and other organs. Treatment options include immunosuppressants, corticosteroids, biologics, and other therapies, with diagnosis supported by blood tests, biopsies, imaging studies, and additional diagnostic tools.

The ANCA associated vasculitis market research report is one of a series of new reports from The Business Research Company that provides ANCA associated vasculitis market statistics, including ANCA associated vasculitis industry global market size, regional shares, competitors with a ANCA associated vasculitis market share, detailed ANCA associated vasculitis market segments, market trends and opportunities, and any further data you may need to thrive in the ANCA associated vasculitis industry. This ANCA associated vasculitis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The antineutrophil cytoplasmic antibody (ANCA) associated vasculitis market size has grown strongly in recent years. It will grow from $0.57 billion in 2024 to $0.63 billion in 2025 at a compound annual growth rate (CAGR) of 9.2%. The growth observed during the historic period can be attributed to increased healthcare expenditure, rising disposable income, a stronger focus on patient-centered care, an expanding middle-class population, greater adoption of telemedicine, and a growing geriatric population.

The antineutrophil cytoplasmic antibody (ANCA) associated vasculitis market size is expected to see strong growth in the next few years. It will grow to $0.88 billion in 2029 at a compound annual growth rate (CAGR) of 9.0%. The growth projected during the forecast period can be attributed to expanding research and clinical trials, increased research and development activities, a rising incidence of autoimmune diseases, growing cases of immune system dysfunction, and a higher prevalence of various associated risk factors. Key trends expected during this period include the rise of personalized medicine, strategic collaborations, advancements in diagnostic testing, increased adoption of telemedicine, and the development of combination therapies.

The increasing prevalence of autoimmune diseases is anticipated to propel the growth of the ANCA-associated vasculitis market in the coming years. Autoimmune diseases occur when the immune system erroneously targets the body's own healthy cells and tissues, mistaking them for harmful invaders such as bacteria or viruses. The rise in these conditions is linked to environmental factors and modern lifestyle habits, with greater exposure to infections and pollutants significantly contributing by disturbing immune tolerance and triggering abnormal immune responses. ANCA-associated vasculitis positively influences advancements in autoimmune disease research and treatment by promoting the development of targeted immunosuppressive therapies, boosting early diagnostic capabilities, and refining overall disease management approaches. These advancements ultimately lead to improved patient outcomes and a deeper insight into immune system regulation. For example, in September 2023, the Impact of IBD Report 2023, published by the Inflammatory Bowel Disease (IBD) Clinical and Research Centre a Canada-based organization dedicated to improving the lives of those with Crohn's disease and ulcerative colitis stated that in 2023, IBD affected 825 per 100,000 Canadians, totaling over 320,000 individuals. With an anticipated annual growth rate of 2.44% in prevalence, it is estimated that by 2035, around 470,000 people, or 1.1% of the Canadian population, will be living with IBD. Consequently, the growing occurrence of autoimmune diseases will support the expansion of the ANCA-associated vasculitis market.

Leading companies in the ANCA-associated vasculitis market are prioritizing the development of innovative solutions such as targeted therapies to offer new treatment options for patients with this rare and severe disease. Targeted therapies for ANCA-associated vasculitis utilize specialized biologic agents that specifically inhibit immune components responsible for inflammation and blood vessel damage, thereby limiting disease advancement and reducing the side effects linked to conventional treatments. For instance, in February 2023, Vifor Fresenius Medical Care Renal Pharma (VFMCRP), a Switzerland-based pharmaceutical firm, received approval from the Therapeutic Goods Administration (TGA) an Australian government regulatory body for Tavneos (avacopan) to treat ANCA-associated vasculitis (AAV) in combination with rituximab or cyclophosphamide-based regimens. This approval is a significant milestone, as Tavneos is the first targeted treatment specifically developed for granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), the two main forms of ANCA-associated vasculitis. The therapy works by selectively blocking the complement C5a receptor (C5aR1), helping to manage inflammation and disease progression while reducing dependence on high-dose glucocorticoids (steroids), which are known for their serious long-term side effects.

In March 2024, Q32 Bio Inc., a U.S.-based clinical-stage biotechnology company, merged with Homology Medicines, Inc. for an undisclosed sum. This merger enables Q32 Bio to enhance its standing as a publicly traded biotech firm by securing resources to further develop key biologic therapies such as bempikibart for autoimmune conditions including atopic dermatitis and alopecia areata, and ADX-097 for complement-mediated disorders, with a Phase 2 trial targeting ANCA-associated vasculitis scheduled for early 2025. Homology Medicines Inc. is a U.S.-based clinical-stage genetic medicines company specializing in treatments for rare diseases.

Major players in the antineutrophil cytoplasmic antibody (anca) associated vasculitis market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., AstraZeneca Plc, Novartis AG, GlaxoSmithKline plc, Amgen Inc., Fresenius Medical Care (FMS), Boehringer Ingelheim International GmbH, Otsuka Holdings Co. Ltd., Biogen Inc., Quest Diagnostics Inc, Csl Behring AG, ARUP Laboratories, Sebia Inc., Exagen Inc., Argenx SE, Arkana Laboratories, Alentis Therapeutics AG, Hansa Biopharma AB, InflaRx NV.

North America was the largest region in the antineutrophil cytoplasmic antibody (ANCA) associated vasculitis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in antineutrophil cytoplasmic antibody (ANCA) associated vasculitis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the antineutrophil cytoplasmic antibody (ANCA) associated vasculitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The antineutrophil cytoplasmic antibody (ANCA) associated vasculitis market consists of revenues earned by entities by providing services such as diagnostic testing, disease management, and patient counseling. The market value includes the value of related goods sold by the service provider or included within the service offering. The antineutrophil cytoplasmic antibody (ANCA) associated vasculitis market also includes sales of biologic therapies, plasma exchange equipment, diagnostic test kits, targeted oral therapies, and monoclonal antibodies. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on antineutrophil cytoplasmic antibody (anca) associated vasculitis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for antineutrophil cytoplasmic antibody (anca) associated vasculitis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The antineutrophil cytoplasmic antibody (anca) associated vasculitis market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Granulomatosis With Polyangiitis (GPA Or Wegener's); Microscopic Polyangiitis (MPA); Eosinophilic Granulomatosis With Polyangiitis (EGPA Or Churg-Strauss); Other Types
• 2) By Treatment: Immunosuppressants; Corticosteroids; Biologics; Other Treatments
• 3) By Diagnosis: Blood Tests; Biopsy; Imaging; Other Diagnosis
• Subsegments:
• 1) By Granulomatosis With Polyangiitis (GPA or Wegener's): Limited Granulomatosis With Polyangiitis; Severe Granulomatosis With Polyangiitis; Refractory Granulomatosis With Polyangiitis
• 2) By Microscopic Polyangiitis (MPA): Renal Microscopic Polyangiitis; Pulmonary Microscopic Polyangiitis; Neurological Microscopic Polyangiitis
• 3) By Eosinophilic Granulomatosis With Polyangiitis (EGPA or Churg-Strauss): Cardiac Eosinophilic Granulomatosis With Polyangiitis; Pulmonary Eosinophilic Granulomatosis With Polyangiitis; Neurological Eosinophilic Granulomatosis With Polyangiitis
• 4) By Other Types: Drug-Induced ANCA-Associated Vasculitis; Infection-Related ANCA-Associated Vasculitis; Overlap Syndrome ANCA-Associated Vasculitis
• Companies Mentioned: F. Hoffmann-La Roche AG; Thermo Fisher Scientific Inc. ; AstraZeneca Plc; Novartis AG; GlaxoSmithKline plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market Characteristics

3. Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market Trends And Strategies

4. Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Growth Analysis And Strategic Analysis Framework

• 5.1. Global Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market Growth Rate Analysis
• 5.4. Global Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Total Addressable Market (TAM)

6. Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market Segmentation

• 6.1. Global Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Granulomatosis With Polyangiitis (GPA Or Wegener's)
• Microscopic Polyangiitis (MPA)
• Eosinophilic Granulomatosis With Polyangiitis (EGPA Or Churg-Strauss)
• Other Types
• 6.2. Global Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Immunosuppressants
• Corticosteroids
• Biologics
• Other Treatments
• 6.3. Global Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Blood Tests
• Biopsy
• Imaging
• Other Diagnosis
• 6.4. Global Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Sub-Segmentation Of Granulomatosis With Polyangiitis (GPA Or Wegener's), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Limited Granulomatosis With Polyangiitis
• Severe Granulomatosis With Polyangiitis
• Refractory Granulomatosis With Polyangiitis
• 6.5. Global Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Sub-Segmentation Of Microscopic Polyangiitis (MPA), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Renal Microscopic Polyangiitis
• Pulmonary Microscopic Polyangiitis
• Neurological Microscopic Polyangiitis
• 6.6. Global Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Sub-Segmentation Of Eosinophilic Granulomatosis With Polyangiitis (EGPA Or Churg-Strauss), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cardiac Eosinophilic Granulomatosis With Polyangiitis
• Pulmonary Eosinophilic Granulomatosis With Polyangiitis
• Neurological Eosinophilic Granulomatosis With Polyangiitis
• 6.7. Global Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Drug-Induced ANCA-Associated Vasculitis
• Infection-Related ANCA-Associated Vasculitis
• Overlap Syndrome ANCA-Associated Vasculitis

7. Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market Regional And Country Analysis

• 7.1. Global Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market

• 8.1. Asia-Pacific Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market

• 9.1. China Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market Overview
• 9.2. China Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market

• 10.1. India Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market

• 11.1. Japan Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market Overview
• 11.2. Japan Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market

• 12.1. Australia Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market

• 13.1. Indonesia Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market

• 14.1. South Korea Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market Overview
• 14.2. South Korea Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market

• 15.1. Western Europe Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market Overview
• 15.2. Western Europe Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market

• 16.1. UK Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market

• 17.1. Germany Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market

• 18.1. France Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market

• 19.1. Italy Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market

• 20.1. Spain Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market

• 21.1. Eastern Europe Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market Overview
• 21.2. Eastern Europe Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market

• 22.1. Russia Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market

• 23.1. North America Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market Overview
• 23.2. North America Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market

• 24.1. USA Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market Overview
• 24.2. USA Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market

• 25.1. Canada Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market Overview
• 25.2. Canada Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market

• 26.1. South America Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market Overview
• 26.2. South America Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market

• 27.1. Brazil Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market

• 28.1. Middle East Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market Overview
• 28.2. Middle East Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market

• 29.1. Africa Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market Overview
• 29.2. Africa Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market Competitive Landscape And Company Profiles

• 30.1. Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market Competitive Landscape
• 30.2. Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market Company Profiles
  • 30.2.1. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AstraZeneca Plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis

31. Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market Other Major And Innovative Companies

• 31.1. Amgen Inc.
• 31.2. Fresenius Medical Care (FMS)
• 31.3. Boehringer Ingelheim International GmbH
• 31.4. Otsuka Holdings Co. Ltd.
• 31.5. Biogen Inc.
• 31.6. Quest Diagnostics Inc
• 31.7. Csl Behring AG
• 31.8. ARUP Laboratories
• 31.9. Sebia Inc.
• 31.10. Exagen Inc.
• 31.11. Argenx SE
• 31.12. Arkana Laboratories
• 31.13. Alentis Therapeutics AG
• 31.14. Hansa Biopharma AB
• 31.15. InflaRx NV

32. Global Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market

34. Recent Developments In The Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market

35. Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market High Potential Countries, Segments and Strategies

• 35.1 Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer
• 250617_r34761_Antineutrophil_Cytoplasmic_Antibody_ANCA_Associated_Vasculitis_GMR_2025

관련자료